Blood transfusion-related side effects
Conditions
Interventions
Traditional DFPP group:Received routine treatment only, without additional infusion of human fibrinogen
DFPP + Fibrinogen Group:Intravenous infusion of 2–3 g human fibrinogen immediately after DFPP treatment
Sponsors
The First Affiliated Hospital of Air Force Military Medical University
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age = 18 years; 2. Patients who meet the clinical indications for DFPP and are scheduled to undergo DFPP; 3. Patients scheduled to receive double filtration plasmapheresis with albumin as the replacement fluid; 4. Voluntary participation in this study and signed informed consent.
Exclusion criteria
Exclusion criteria: 1. Coagulation disorders before DFPP 2. Congenital fibrinogen deficiency; 3. History of allergy to human fibrinogen; 4. Shock complicated with tissue hypoperfusion; 5. evere liver failure; 6. Systemic anticoagulation within 24 hours (heparin / low-molecular-weight heparin / aspirin / clopidogrel / ticagrelor / rivaroxaban / dabigatran / argatroban); 7. Pregnant or lactating women; 8. Active infectious diseases, such as hepatitis B, syphilis, HIV, etc.; 9. Contraindications to sodium citrate or nafamostat mesilate.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of coagulation dysfunction; | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of filter failure;Changes in coagulation function indicators before and after treatment;Volume of blood transfusion after treatment;Changes in Sequential Organ Failure Assessment (SOFA) score;Bleeding events;Incidence of drug allergy to human fibrinogen; | — |
Countries
China
Contacts
Public ContactMing Bai
The First Affiliated Hospital of Air Force Military Medical University
Outcome results
None listed